Glycinebetaine

Glycinebetaine

SCHEMBL2803780

C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BHMTBHMT2

The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
APEX1 P27695 1/20 0.50
SLC22A16 Q86VW1 1/20 0.46
CPT2 P23786 1/20 0.42
CPT1A P50416 1/20 0.42
BBOX1 O75936 6/20 0.40
CA4 P22748 2/20 0.39
FFAR3 O14843 2/20 0.38
HDAC3 O15379 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
HRH1 P35367 1/20 0.37
KMT2A Q03164 1/20 0.37
CRAT P43155 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycinebetaine SCHEMBL7739 1.00
Glycinebetaine SCHEMBL8678519 1.00 TSHR (0.53) TSHRALDH1A1LMNAAPEX1SLC22A16
Betaine SCHEMBL31467313 1.00
Glycinebetaine SCHEMBL4900209 1.00
Glycinebetaine SCHEMBL11109389 0.97
Glycinebetaine SCHEMBL4255367 0.97
Glycinebetaine SCHEMBL8388807 0.97
Glycinebetaine SCHEMBL4457941 0.97 TSHR (0.50) TSHRALDH1A1LMNAAPEX1SLC22A16
Glycinebetaine SCHEMBL20703289 0.97
Glycinebetaine SCHEMBL61181 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024149047-A1 CRYOPRESERVATION SOLUTION BASED ON LIQUID-LIQUID CONDENSED PHASE, PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院化学研究所 2024-07-18 WO disclosed
EP-3537876-B1 ANTHELMINTHIC COMPOSITION AGRESEARCH LTD (NZ) 2024-04-10 EP disclosed
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 WO disclosed
CN-117202888-A Multiphase liquid compositions with improved deposition of active ingredients 法国特种经营公司 2023-12-08 CN disclosed
CN-113950374-B Arrangement of reagents in an analysis device 维迪亚控股有限公司 2023-07-28 CN disclosed
EP-4190551-A1 METHOD FOR USING A NANOMESH MULTILAYER BODY Mitsubishi Chemical Corporation (JP) 2023-06-07 EP disclosed
US-20220143597-A1 DISPOSITION OF REAGENTS IN ASSAY DEVICE VIDYA HOLDINGS LTD (GB) 2022-05-12 US disclosed
US-20220146505-A1 DISPOSITION OF REAGENTS IN ASSAY DEVICE VIDYA HOLDINGS LTD (GB) 2022-05-12 US disclosed
US-20220055340-A1 NANOMESH MULTILAYER BODY, METHOD FOR PRODUCING CONDUCTIVE CIRCUIT AND NANOMESH BONDING KIT MITSUBISHI CHEMICAL CORPORATION (JP) 2022-02-24 US disclosed
CN-113950373-A Arrangement of reagents in an analytical device 维迪亚控股有限公司 2022-01-18 CN disclosed
EP-0824345-A4 S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY ORIDIGM CORP (US) 1999-08-25 EP disclosed
EP-0828853-A4 IMPROVED METHOD FOR NUCLEOTIDE SEQUENCE AMPLIFICATION GENZYME CORP (US) 1998-05-13 EP disclosed
EP-0828853-A1 IMPROVED METHOD FOR NUCLEOTIDE SEQUENCE AMPLIFICATION GENZYME CORPORATION (US) 1998-03-18 EP disclosed
EP-0824345-A1 S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY ORIDIGM CORPORATION (US) 1998-02-25 EP disclosed
EP-0742838-A1 METHODS FOR THE ELIMINATION OF DNA SEQUENCING ARTIFACTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-11-20 EP disclosed
WO-1996033703-A2 S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY ORIDIGM CORPORATION (US) 1996-10-31 WO disclosed
US-5545539-A PLYMERASE CHAIN REACTION, N,N,N-TRIMETHYLGLYCINE USED AS AMPLIFIER AGENT, TARGET TRINUCLEOTIDE REPEAT SEQUENCE, INDICATIVE OR HUNTINGTON'S DISEASE GENZYME CORPORATION (US) 1996-08-13 US disclosed
WO-1996012041-A1 IMPROVED METHOD FOR NUCLEOTIDE SEQUENCE AMPLIFICATION GENZYME CORPORATION (US) 1996-04-25 WO disclosed
WO-1995020682-A1 METHODS FOR THE ELIMINATION OF DNA SEQUENCING ARTIFACTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-08-03 WO disclosed
US-4212966-A AGITATING MELT WITH SURFACTANT TO FORM DISPERSION NATIONAL DISTILLERS & CHEMICAL CORPORATION (US) 1980-07-15 US disclosed